Pyxis Oncology's US$8.9m Market Cap Fall Books Insider Losses

The recent 11% drop in Pyxis Oncology, Inc.'s (NASDAQ:PYXS) stock could come as a blow to insiders who purchased US$174.4k worth of stock at an average buy price of US$1.96 over the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth US$106.6k which is not ideal.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Pyxis Oncology

The Last 12 Months Of Insider Transactions At Pyxis Oncology

In the last twelve months, the biggest single purchase by an insider was when CFO & COO Pamela Connealy bought US$174k worth of shares at a price of US$2.00 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$1.20). Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Pamela Connealy was the only individual insider to buy during the last year.

The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Does Pyxis Oncology Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that Pyxis Oncology insiders own 6.5% of the company, worth about US$4.7m. We do generally prefer see higher levels of insider ownership.

So What Do The Pyxis Oncology Insider Transactions Indicate?

It doesn't really mean much that no insider has traded Pyxis Oncology shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Pyxis Oncology stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example, Pyxis Oncology has 4 warning signs (and 2 which shouldn't be ignored) we think you should know about.

But note: Pyxis Oncology may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.